Hematologic Malignancy (Second Edition)

Dear Colleagues,

This collection is the second edition of the Special Issue "Hematologic Malignancy".

Hematologic malignancies have always represented a highly dynamic field for biologic and translational research that rapidly impacts the clinical practice.

Recently, the ever more refined risk stratifications, based on molecular biomarkers and minimal residual disease assessment, and the advent of novel targeted agents have increased the complexity of the clinical approach. Therefore, clinical decision making and patient management have become even more challenging, bearing a particular impact on allogeneic transplant indications.

The deeper understanding of the biologic characteristics of many hematologic malignancies and, in particular, of their genomic landscape, allowed the identification of specific therapeutic targets that have profoundly modified the treatment of patients.

Among these new therapeutic modalities, we can cite in lymphoblastic leukemias and lymphomas the advent of innovative immunologic approaches, such as monoclonal antibodies, Bite, Darts, checkpoint inhibitors and CAR-T cell, while in acute myeloid leukemias, the molecular-based therapies and the new cytotoxic formulations, such as FLT3 inhibitors, gentuzumab/ozogamycin, CPX351.

In chronic myeloproliferative neoplasms, multiple myeloma and chronic lymphocytic leukemia, a continuous effort is ongoing to tailor the treatment to patient and disease characteristics in order to optimize the use of the numerous biologic and targeted therapies.

It is therefore a great pleasure to invite you to contribute to the current Special Issue. Its aim is to gather the most recent advances in the biological and clinical aspects of hematologic malignancies, with research as well as review articles addressing the state-of-the-art and the future perspectives of hematologic malignancies, focusing preferentially on innovative research in biology, diagnosis, prognosis and therapy.

You may choose our Joint Special Issue in Cancers.

Dr. Nicola Stefano Fracchiolla
Dr. Francesco Onida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.